ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
3.447
-0.023 (-0.66%)
Jan 31, 2025, 9:54 AM EST - Market open
ImmunityBio Revenue
ImmunityBio had revenue of $6.11M in the quarter ending September 30, 2024, with 7,346.34% growth. This brings the company's revenue in the last twelve months to $7.33M, up 1,218.71% year-over-year. In the year 2023, ImmunityBio had annual revenue of $622.00K with 159.17% growth.
Revenue (ttm)
$7.33M
Revenue Growth
+1,218.71%
P/S Ratio
n/a
Revenue / Employee
$11,675
Employees
628
Market Cap
2.52B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
IBRX News
- 2 days ago - ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
- 4 days ago - ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
- 13 days ago - ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval - Seeking Alpha
- 14 days ago - ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
- 15 days ago - ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency - Business Wire
- 15 days ago - ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom - Business Wire
- 25 days ago - ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective - Business Wire
- 6 weeks ago - ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha